Related Experiment Video
Updated: May 20, 2026
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
Changing paradigms with molecular imaging of neuroendocrine tumors
Michael S Hofman1, Rodney J Hicks
1Centre for Cancer Imaging, Peter MacCallum Cancer Centre, East Melbourne, Victoria 3185, Australia.
Abstract:
Molecular imaging is changing diagnostic and treatment paradigms in patients with neuroendocrine tumors through its ability to non-invasively characterize disease, supplementing the traditional role of using imaging for localizing and measuring disease. For patients with metastatic disease, there is an increasing range of therapies but these must be individualized to the specific subtype of tumor expressed, which varies in aggressiveness from well to poorly differentiated phenotypes. Positron emission tomography (PET) is now able to characterize these subtypes through its ability to quantify somatostatin receptor cell surface (SSTR) expression and glycolytic metabolism with SSTR and fluorodeoxyglucose (FDG) PET, respectively. The ability to perform this as a whole body study is highlighting the limitations of relying on histopathology obtained from a single site. Through earlier diagnosis, improved selection of the most appropriate therapy and better assessment of therapeutic response for an individual patient, molecular imaging is improving the outcome for patients with NET.
Insights
Molecular imaging, using somatostatin receptor (SSTR) and fluorodeoxyglucose (FDG) PET scans, helps individualize neuroendocrine tumor (NET) treatment by characterizing subtypes and assessing response, improving patient outcomes.
Area of Science:
- Oncology
- Radiology
- Nuclear Medicine
Background:
- Molecular imaging advances diagnostic and treatment strategies for neuroendocrine tumors (NETs).
- Individualized therapy selection is crucial for metastatic NETs, considering tumor aggressiveness and subtype.
- Traditional imaging focuses on localization and measurement, but molecular imaging offers deeper characterization.
Purpose of the Study:
- To highlight the role of molecular imaging in characterizing NET subtypes.
- To demonstrate how PET imaging can quantify somatostatin receptor (SSTR) expression and glycolytic metabolism.
- To emphasize the benefits of whole-body molecular imaging over single-site histopathology for NET management.
Main Methods:
- Utilizing Positron Emission Tomography (PET) with SSTR-targeted radiotracers to assess cell surface receptor expression.
- Employing fluorodeoxyglucose (FDG) PET to quantify tumor glycolytic metabolism.
- Performing whole-body PET studies for comprehensive disease assessment.
Main Results:
- PET imaging can differentiate NET subtypes based on SSTR and FDG uptake.
- Whole-body imaging reveals limitations of single-site histopathology.
- Molecular imaging provides a more comprehensive assessment of metastatic disease.
Conclusions:
- Molecular imaging enables earlier diagnosis and precise characterization of NET subtypes.
- It facilitates the selection of individualized therapies based on tumor biology.
- Improved assessment of therapeutic response through molecular imaging enhances patient outcomes in NET.
